- Tytuł:
- Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
- Autorzy:
- Źródło:
- In The Lancet Infectious Diseases
Czasopismo naukowe